Cannabis for Athletic Pain & DOMS: What CBD Actually Does

The Cellular Mechanism: PPARγ, TRPV1, Adenosine A2A Strong evidence

The cellular and animal evidence for CBD's anti-inflammatory action is well-characterized. The most-cited synthesis is Atalay, Jarocka-Karpowicz & Skrzydlewska (Antioxidants, 2019; doi:10.3390/antiox9010021), which reviewed the mechanisms across multiple models. The core pathways:

• PPARγ — a nuclear receptor that, when activated, suppresses pro-inflammatory gene transcription. CBD acts as a PPARγ agonist, reducing NF-κB-driven cytokine production.
• TRPV1 — the vanilloid receptor activated by capsaicin and noxious heat. CBD desensitizes TRPV1 over time, reducing pain signaling at the peripheral and central level.
• Adenosine A2A — CBD inhibits adenosine reuptake, raising extracellular adenosine and producing A2A-mediated immunosuppression and anti-inflammatory effects.
• 5-HT1A — CBD modulates serotonergic signaling, with downstream effects on inflammatory and anxiety circuits.

This is a coherent and well-replicated mechanistic picture. The challenge is that cellular evidence is not athlete evidence, and the gap between in-vitro/preclinical findings and a measurable clinical effect in trained humans is the central issue with the CBD-and-pain story.

Athlete-Specific Clinical Evidence: Thin, Mixed ⚠️ Emerging

Two systematic reviews from Sports Medicine - Open are the cleanest summaries. McCartney et al. (Sports Medicine - Open, 2020) reviewed CBD in sport-and-exercise contexts and found preliminary signal across multiple endpoints (anxiety, sleep, pain, inflammation) with substantial methodological heterogeneity and small samples. Burr et al. (Sports Medicine - Open, 2021) characterized the field bluntly as "preliminary, at times inconsistent" with mostly preclinical underpinnings.

The more recent muscle-damage trials report mixed signals. Cochrane et al. (JFMK, 2025) and Isenmann et al. (Sports Medicine, 2024) tested CBD doses of 60-300 mg post-resistance exercise. The pattern across these and earlier trials (Hatchett et al., JFMK, 2020; Cochran-Biederman et al., Sports Medicine - Open, 2021): modest reductions in self-reported soreness, limited objective biomarker change. A 2024 Sahinovic et al. trial reported reduced creatine kinase 72 hours after resistance exercise at 60 mg — the kind of single-finding signal that needs replication before becoming the basis of a recommendation.

Topical CBD: Local Action, Minimal Systemic Risk

Topical CBD has a distinct pharmacology from oral CBD. Hammell et al. (European Journal of Pain, 2016) demonstrated minimal systemic absorption in rats, confirmed by the broader topical-cannabinoid review by Bruni et al. (Molecules, 2018). The mechanism is local: anti-inflammatory action at the application site, possible counterirritant effects, and some evidence of CBD acting at peripheral CB2 receptors on local immune cells.

For athletes, two practical implications follow:

• Topical CBD poses near-zero positive-test risk. Topical THC contamination remains a theoretical concern but is not a documented cause of athlete AAFs. Tested athletes should still verify product purity via NSF Certified for Sport — the much more common contamination route is oral CBD products with undisclosed THC, not topicals.
• Topical CBD also produces near-zero systemic effect. Athletes hoping for systemic anti-inflammatory action equivalent to NSAIDs should expect that to come from oral or sublingual dosing, not topical balms.

Contamination Context for Pain Products

The CBD-product contamination problem is the single most important practical concern for tested athletes using oral CBD for pain or inflammation. Bonn-Miller et al. (JAMA, 2017) tested 84 online CBD products and found THC in 21.43% of samples (up to 6.43 mg/mL), 26% with less CBD than labeled, 43% with more, and 69% mislabeled overall for CBD concentration. Multiple UFC, MMA, and Olympic-track positives have been traced to "trusted the label" CBD use. For the deeper dive, see THC contamination risk.

The federal hemp landscape is also shifting under athletes' feet. Public Law 119-37 § 781 (signed November 12, 2025, effective November 12, 2026) caps finished hemp-derived cannabinoid products at 0.4 mg total THC per container — a change the U.S. Hemp Roundtable estimates will eliminate roughly 95% of currently-sold products. Athletes' compliance posture should already be NSF-Certified-for-Sport oral CBD plus topicals; that posture survives the transition with minimal disruption.

The Opioid-Sparing Frame

The most cogent case for cannabis (and CBD) in athletic pain is not that it out-performs NSAIDs or ice on DOMS. It is that it may displace opioid use in injury and post-surgical contexts where NFL, NBA, and elite-level pain management has historically depended on prescribed opioids. Eugene Monroe's May 23, 2016 Players' Tribune op-ed "Getting Off the T Train" was the first by an active NFL player to publicly call for the league to remove cannabis from testing and address opioid dependence: "the NFL relies heavily on opioids to get players back on the field as soon as possible, but studies have shown medical marijuana to be a much better solution; it is safer, less addictive and can even reduce opioid dependence."

The opioid-sparing case in athletes is built largely from general-population evidence and clinical experience rather than athlete-specific randomized trials — which is a real evidence gap, but it is also the most coherent harm-reduction frame for a population at elevated risk of post-injury opioid dependence. The NFL Joint Pain Management Committee's 2022 funding of UC San Diego (Wallace and Marcotte) and University of Regina (Neary) was explicitly motivated by this question. See Eugene Monroe op-ed and NFL cannabis policy for the policy context.